Ciclosporin A therapy is associated with disturbances in glucose metabolism in dogs with atopic dermatitis

Veterinary Dermatology

Volumn 22, Issue 2, 2011, Pages 173-180

  Kovalik, Marcel ^a   Thoday, Keith L ^a   Handel, Ian G ^a   de C Bronsvoort, Barend M ^a   Evans, Helen ^b   van den Broek, Adri H M ^a   Mellanby, Richard J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Cambridge Specialist Laboratory Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DERMATOLOGICAL AGENT; FRUCTOSAMINE; GLUCAGON; IMMUNOSUPPRESSIVE AGENT; INSULIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; BLOOD; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ADMINISTRATION; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; MALE; METABOLISM; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRUCTOSAMINE; GLUCAGON; IMMUNOSUPPRESSIVE AGENTS; INSULIN; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 79952343958     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2010.00935.x     Document Type: Article

References (51)

1. Viola JP, Rao A. Role of the cyclosporin-sensitive transcription factor NFAT1 in the allergic response. Memorias Do Instutio Oswaldo Cruz 1997; 92(Suppl. 2): 147-55.
2. Robson D. Review of the properties and mechanisms of action of cyclosporine with an emphasis on dermatological therapy in dogs, cats and people. Veterinary Record 2003; 152: 768-72.
3. Olivry T, Rivierre C, Jackson HA et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Veterinary Dermatology 2002; 13: 77-87.
4. Olivry T, Mueller RS. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Veterinary Dermatology 2003; 14: 121-46.
5. Griffiths LG, Sullivan M, Borland WW. Cyclosporin as the sole treatment for anal furunculosis: preliminary results. Journal of Small Animal Practice 1999; 40: 569-72.
6. Doust R, Griffiths LG, Sullivan M. Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs. Veterinary Record 2003; 152: 225-9.
7. Linek M, Boss C, Haemmerling R et al. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. Journal of the American Veterinary Medical Association 2005; 226: 59-64.
8. Olivry T, Rivierre C, Murphy KM. Efficacy of cyclosporine for treatment induction of canine pemphigus foliaceus. Veterinary Record 2003; 152: 53-4.
9. Guaguère E. Efficacy of cyclosporin in the treatment of idiopathic sterile nodular panniculitis in two dogs [abstract]. Veterinary Dermatology 2000; 11(Suppl. 1): 22.
10. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Veterinary Dermatology 2006; 17: 3-16.
11. Adamo FR, O'Brien RT. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. Journal of the American Veterinary Medical Association 2004; 225: 1211-6.
12. Bexfield NH, Watson PJ, Herrtage ME. Management of myasthenia gravis using cyclosporine in 2 dogs. Journal of Veterinary Internal Medicine 2006; 20: 1487-90.
13. Mori Y, Suko M, Okudaira H et al. Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 1986; 29: 244-7.
14. Feutren G, Assan R, Karsenty G et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2: 119-24.
15. Carel J-C, Boitard C, Eisenbarth G et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. Journal of Autoimmunity 1996; 9: 739-45.
16. De Filippo G, Carel JC, Boitard C et al. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 1996; 45: 101-4.
17. Engfeldt P, Tyden G, Gunnarsson R et al. Impaired glucose-tolerance with cyclosporine. Transplantation Proceedings 1986; 18: 65-6.
18. van Schilfgaarde R, van der Burg MP, van Suylichem PT et al. Interference by cyclosporine with the endocrine function of the canine pancreas. Transplantation 1987; 44: 13-6.
19. Robertson RP, Franklin G, Nelson L. Glucose homeostasis and insulin secretion during chronic treatment with cyclosporine in nondiabetic humans. Diabetes 1989; 38: 99-100.
20. Gores PF, Boudreaux JP, Hesse UJ et al. Canine islet autografts with and without administration of cyclosporine. Surgery 1987; 101: 557-61.
21. Yamamoto H, Akazawa S, Yamaguchi Y et al. Effects of cyclosporine-A and low dosages of steroid on postransplantation diabetes in kidney-transplant recipents. Diabetes Care 1991; 14: 867-70.
22. Krentz AJ, Dousset B, Mayer D et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993; 42: 1753-9.
23. Gunnarsson R, Klintmalm G, Lundgren G et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplantation Proceedings 1984; 16: 709-12.
24. Ishizuka J, Gugliuzza KK, Wassmuth Z et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486-90.
25. Alejandro R, Feldman EC, Bloom AD et al. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38: 698-703.
26. Wahlstrom HE, Lavelle-Jones M, Endres D et al. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation 1990; 49: 600-4.
27. Murray SC, Gasser A, Hess RS. Transient hyperglycaemia in a prediabetic dog treated with prednisone and cyclosporin A. Australian Veterinary Journal 2009; 87: 352-5.
28. Fontaine J, Olivry T. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study. Veterinary Record 2001; 148: 662-3.
29. Olivry T, Steffan J, Fisch RD et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002; 221: 370-7.
30. Steffan J, Parks C, Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. Journal of the American Veterinary Medical Association 2005; 226: 1855-63.
31. Steffan J, Alexander D, Brovedani F et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Veterinary Dermatology 2003; 14: 11-22.
32. Basadonna G, Montorsi F, Kakizaki K et al. Cyclosporin-A and islet function. American Journal of Surgery 1988; 156: 191-3.
33. DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Veterinary Immunology and Immunopathology 2001; 81: 271-6.
34. Watson PJ, Herrtage ME. Use of glucagon stimulation tests to assess β-cell function in dogs with chronic pancreatitis. Journal of Nutrition 2004; 134: 2081-3.
35. Fall T, Holm B, Karlsson A et al. Glucagon stimulation test for estimating endogenous insulin secretion in dogs. Veterinary Record 2008; 163: 266-70.
36. Griffiths LG, Sullivan M, Borland WW. Cyclosporin as the sole treatment for anal furunculosis: preliminary results. Journal of Small Animal Practice 1999; 40: 569-72.
37. Olivry T, Marsella R, Iwasaki T et al. Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Veterinary Dermatology 2007; 18: 78-86.
38. Colombo S, Hill PB, Shaw DJ et al. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study. Veterinary Dermatology 2005; 16: 162-70.
39. R Development Core Team. R. A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2009.
40. Loste A, Marca MC, Perez M et al. Clinical value of fructosamine measurements in non-healthy dogs. Veterinary Research Communications 2001; 25: 109-15.
41. Graham PA, Maskell E, Rawlings JM et al. Influence of a high fibre diet on glycaemic control and quality of life in dogs with diabetes mellitus. Journal of Small Animal Practice 2002; 43: 67-73.
42. Dutoit DF, Reecesmith H, McShane P et al. Effect of cyclosporin A on allotransplanted pancreatic fragments to the spleen of totally pancreatectomized dogs. Transplantation 1982; 33: 302-7.
43. Merrell RC, Mahoney ME, Basadonna G et al. Failure of canine islet allografts and autografts with cyclosporine. Surgery 1985; 98: 324-9.
44. Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal-allograft recipients. Transplantation 1987; 44: 376-81.
45. Menegazzo LA, Ursich MJ, Fukui RT et al. Mechanism of the diabetogenic action of cyclosporin A. Hormone and Metabolic Research 1998; 30: 663-7.
46. Dean SK, Scott H, Keogh GW et al. Effect of immunosuppressive doses of cyclosporine on pancreatic beta cell function in pigs. American Journal of Veterinary Research 2002; 63: 1501-6.
47. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986; 35: 1049-52.
48. Shi CL, Rooth P, Taljedal IB. Effects of cyclosporin A and verapamil on mouse pancreatic islets. Acta Endocrinologica (Copen-hagen) 1993; 129: 54-8.
49. Marchetti P, Kneteman NM, Swanson CJ et al. Effect of cyclosporin treatment on metabolic and hormonal responses to mixed meal plus oral glucose in dogs with intrasplenic pancreatic islet autograft. Research in Experimental Medicine 1994; 194: 45-52.
50. Lindholm A, Henricsson S, Lind M et al. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. European Journal of Clinical Pharmacology 1988; 34: 461-4.
51. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplantation Proceedings 1990; 22: 1110-2.